Group 1: Marketing Strategies - The Pharmaceutical Business Group focuses on becoming the "first brand" in pain management, leveraging the efficacy of Yunnan Baiyao products in this field [2] - Significant growth in aerosol and plaster products, with a comprehensive marketing strategy integrating various channels and scenarios [2][3] - Online sales increased by over 20%, with a total of 48.45 million visitors and 3.54 million consumers generated through e-commerce platforms, resulting in a GMV of 254 million yuan [3] Group 2: Dividend Distribution - For the 2024 fiscal year, the company will distribute a cash dividend of 11.85 yuan per 10 shares, totaling approximately 2.16 billion yuan, which is 90.09% of the net profit attributable to shareholders [4] - The total cash dividend for 2024, including special dividends, amounts to 23.98 yuan per 10 shares, with a total of 4.28 billion yuan [4][5] - In the first half of 2025, a cash dividend of 10.19 yuan per 10 shares will be distributed, totaling 1.82 billion yuan, representing 50.05% of the net profit for that period [5] Group 3: Future Product Development - The Health Products Business Group aims to be a leader in high-quality health products, focusing on oral care and expanding the product ecosystem [6] - Continuous enhancement of the oral product line and development of new products to strengthen market position [6] Group 4: R&D Planning - The company emphasizes innovation-driven development, focusing on both traditional Chinese medicine and innovative pharmaceuticals [7] - Ongoing projects include 16 major traditional Chinese medicine varieties and 37 development projects, with a focus on innovative drug development [8] - Short-term projects aim to enhance existing products, while long-term projects focus on innovative drug development aligned with social needs and technological advancements [8]

Group 1: Pharmaceutical Business Growth - The pharmaceutical segment aims for significant growth in 2024 by focusing on becoming the leading brand in pain management, enhancing product efficacy, and expanding its ecosystem [2] - Clinical research on core products like Yunnan Baiyao (powder) and capsules for diabetic foot and skeletal pain has shown steady progress, opening broader application scenarios [4] - Marketing strategies, including the successful promotion of the self-owned sports IP "Let's Go Play Ball," have improved brand youthfulness and product penetration [4] Group 2: Health Products Channel Development - The company maintains a comprehensive national sales team for health products, with Yunnan Baiyao toothpaste leading the market share in the oral care category [5] - Continuous optimization of the entire channel has strengthened traditional offline advantages while exploring new retail formats, enhancing market competitiveness [5] Group 3: Provincial Pharmaceutical Company Performance - In 2024, the Provincial Pharmaceutical Company achieved a main business revenue of CNY 24.607 billion, a year-on-year increase of 0.48% [6] - Non-pharmaceutical business areas like medical devices and special medical foods saw a sales growth of 14% [7] - The OTC segment experienced an 18% sales increase, while the new specialty pharmacy model grew by 29% [7] Group 4: Future Investment and Acquisition Plans - The company plans to optimize its industrial portfolio through both "internal" and "external" collaborative development, focusing on strategic mergers and partnerships to overcome growth bottlenecks [8]